ImmunityBio, Inc. (IBRX) director reports 146,020 stock options grant

Rhea-AI Filing Summary

ImmunityBio, Inc. director reported receiving a new stock option grant for 146,020 shares of common stock at an exercise price of $2.36 per share, expiring on December 12, 2035.

The award was granted under the 2025 Equity Incentive Plan and vests in three annual installments, with 48,673 options vesting on December 12, 2026, 48,673 on December 12, 2027 and 48,674 on December 12, 2028, as long as the director continues as a service provider.

Any unvested options will fully vest immediately before a Change in Control, as defined in the 2025 Equity Incentive Plan, if the director remains a service provider through that date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Wendel Bruce

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	146,020	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 146,020 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wendel Bruce

(Last) (First) (Middle)

C/O IMMUNITYBIO, INC.

3530 JOHN HOPKINS COURT

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ImmunityBio, Inc. [ IBRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.36	12/12/2025		A		146,020		(1)	12/12/2035	Common Stock	146,020	$0	146,020	D

Explanation of Responses:

1. Subject to the reporting person's continuing to be a Service Provider (as defined in the 2025 Equity Incentive Plan) through each applicable vesting date, 48,673 of the shares subject to the award will vest on December 12, 2026, 48,673 of the shares subject to the award will vest on December 12, 2027 and 48,674 of the shares subject to the award will vest on December 12, 2028, such that the award will be fully vested on December 12, 2028; provided that, notwithstanding the foregoing, any unvested shares subject to the award will fully vest immediately prior to a Change in Control (as defined in the 2025 Equity Incentive Plan), subject to the reporting person continuing to be a Service Provider through the date of such Change in Control.

Remarks:

	/s/ Philip LoScalzo, as Attorney-in-Fact	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ImmunityBio (IBRX) report in this Form 4?

A director of ImmunityBio, Inc. reported receiving a stock option for 146,020 shares of common stock at an exercise price of $2.36 per share, expiring on December 12, 2035.

What is the reporting person’s relationship to ImmunityBio (IBRX)?

The reporting person is a director of ImmunityBio, Inc., and the Form 4 indicates it was filed by one reporting person.

How do the ImmunityBio (IBRX) stock options granted to the director vest?

Subject to continued service, 48,673 options vest on December 12, 2026, another 48,673 on December 12, 2027, and 48,674 on December 12, 2028, so the award is fully vested on December 12, 2028.

When do the newly granted ImmunityBio (IBRX) stock options expire?

The stock options granted to the director have an expiration date of December 12, 2035, if not exercised or forfeited earlier under the plan terms.

Under what conditions do the ImmunityBio (IBRX) options vest early?

Any unvested options will fully vest immediately prior to a Change in Control, as defined in the 2025 Equity Incentive Plan, if the director continues as a service provider through the Change in Control date.